Xcovery Holdings, Inc. Email Format
Pharmaceutical ManufacturingFlorida, United States11-50 Employees
Xcovery Holdings, Inc. is a biopharmaceutical company in the pharmaceutical manufacturing sector focused on discovering and developing medicines to treat advanced tumors, with a pipeline of oncology therapies targeting a range of malignant diseases. It is based in Miami, Florida, at 168 Southeast 1st Street Suite 1100, 33131, United States, and employs 11-50 people; more information is available on its website at https://xcovery.com. In December 2024, the U.S. Food and Drug Administration approved ensartinib (Ensacove) for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor, with full prescribing information posted on Drugs@FDA. Xcovery collaborates with Betta Pharmaceuticals on X-396, a next-generation ALK inhibitor in development for lung cancer. In 2026, the company announced the launch of ENSACOVE (ensartinib) and entered into an agreement with EVERSANA to support and expand its U.S. commercialization.